| Index | — | P/E | 21.22 | EPS (ttm) | 4.29 | Insider Own | 1.93% | Shs Outstand | 158.31M | Perf Week | 2.10% |
| Market Cap | 14.41B | Forward P/E | 9.65 | EPS next Y | 9.43 | Insider Trans | -0.34% | Shs Float | 143.41M | Perf Month | 1.22% |
| Enterprise Value | 17.97B | PEG | 1.78 | EPS next Q | 2.17 | Short Float | 3.44% | Perf Quarter | 2.19% | ||
| Income | 703.00M | P/S | 1.09 | EPS this Y | 4.15% | Short Ratio | 2.95 | Perf Half Y | 12.62% | ||
| Sales | 13.25B | P/B | 1.33 | EPS next Y | 8.94% | ROA | 1.11% | Short Interest | 4.93M | Perf YTD | 17.46% |
| Book/sh | 68.28 | P/C | 72.40 | EPS next 5Y | 11.95% | ROE | 6.43% | 52W High | 96.77 -5.93% | Perf Year | 23.99% |
| Cash/sh | 1.26 | P/FCF | 20.82 | EPS past 3/5Y | -14.96% 1.93% | ROIC | 1.11% | 52W Low | 69.02 31.89% | Perf 3Y | 89.25% |
| Dividend Est. | 2.02 (2.22%) | EV/EBITDA | 14.25 | Sales past 3/5Y | 3.21% -0.14% | Gross Margin | 35.70% | Volatility | 1.93% 2.29% | Perf 5Y | 228.39% |
| Dividend TTM | 1.93 (2.12%) | EV/Sales | 1.36 | EPS Y/Y TTM | -48.68% | Oper. Margin | 6.83% | ATR (14) | 2.17 | Perf 10Y | 154.20% |
| Dividend Ex-Date | Oct 30, 2026 | Quick Ratio | 17.97 | Sales Y/Y TTM | 3.26% | Profit Margin | 5.30% | RSI (14) | 47.89 | Recom | 2.50 |
| Dividend Gr. 3/5Y | 11.78% 9.07% | Current Ratio | 17.97 | EPS Q/Q | 4.35% | SMA20 | -0.81% | Beta | 0.24 | Target Price | 101.71 |
| Payout | 43.76% | Debt/Eq | 0.35 | Sales Q/Q | -1.64% | SMA50 | -1.37% | Rel Volume | 1.30 | Prev Close | 91.02 |
| Employees | 10,797 | LT Debt/Eq | 0.35 | Earnings | Feb 04 | SMA200 | 8.22% | Avg Volume | 1.62M | Price | 91.03 |
| IPO Date | Nov 06, 1986 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.00% -0.28% | Net Debt/EBITDA | 2.83 | Volume | 2,099,495 | Change | 0.01% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | Barclays | Overweight | $110 → $109 |
| Aug-24-26 | Reiterated | Morgan Stanley | Equal Weight | $87 → $92 |
| Jul-15-26 | Reiterated | Atlantic Equities | $81 → $88 | |
| Jul-10-26 | Reiterated | Jefferies | Buy | $115 → $123 |
| Jul-07-26 | Reiterated | UBS | Neutral | $85 → $94 |
| Jul-07-26 | Reiterated | Evercore ISI Group | Outperform | $103 → $106 |
| Jul-06-26 | Reiterated | Wolfe Research | Outperform | $100 |
| Jul-06-26 | Reiterated | Barclays | Overweight | $95 → $110 |
| May-21-26 | Reiterated | Morgan Stanley | Equal Weight | $85 → $87 |
| Apr-30-26 | Reiterated | Truist Securities | Buy | $70 → $96 |
Unum Group, along with its various subsidiaries, specializes in delivering financial protection benefits, primarily operating across the United States, the United Kingdom, and Poland. The company's operations are organized into distinct segments: Unum US, Unum International, Colonial Life, and the Closed Block. Its extensive product portfolio encompasses group coverage, including long-term and short-term disability, life insurance, and accidental death and dismemberment. Additionally, Unum provides a range of supplemental and voluntary offerings like individual disability, various voluntary benefits, and dental and vision plans. Further offerings include policies addressing accidents, sickness, general disability, life coverage, cancer, and critical illness. Beyond these, Unum's services extend to group pension plans, individual life insurance, corporate-owned life insurance (COLI), and the management of reinsurance pools. Its primary clientele consists of employers, who procure these solutions to benefit their workforce. Distribution is handled via a diverse network comprising in-house field sales teams, independent brokers, consultants, and an independent contractor agency sales force. Established in 1848, Unum Group maintains its headquarters in Chattanooga, Tennessee.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 13,247 | 13,054 | 12,790 | 12,309 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 8,517 | 8,065 | 8,046 | 8,276 | — | — | — | — | — | |
| Gross Profit | 4,729 | 4,989 | 4,744 | 4,032 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,344 | 0 | 1,166 | 1,163 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 2,480 | 4,056 | 1,327 | 1,229 | — | — | — | — | — | |
| Operating Income | 906 | 934 | 2,251 | 1,640 | — | — | — | — | — | |
| Interest Expense | 211 | 209 | 201 | 195 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 211 | 209 | 201 | 195 | — | — | — | — | — | |
| Net Income Before Taxes | 906 | 934 | 2,251 | 1,640 | — | — | — | — | — | |
| Income Taxes | 203 | 195 | 472 | 356 | — | — | — | — | — | |
| Consolidated Net Income | 703 | 739 | 1,779 | 1,284 | — | — | — | — | — | |
| Net Income From Continuing Operations | 703 | 739 | 1,779 | 1,284 | — | — | — | — | — | |
| Net Income | 703 | 739 | 1,779 | 1,284 | — | — | — | — | — | |
| EPS (Recurring) | 4.29 | 4.28 | 9.49 | 6.53 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 4.29 | 4.28 | 9.49 | 6.53 | — | — | — | — | — | |
| EPS (Diluted) | 4.29 | 4.28 | 9.46 | 6.50 | — | — | — | — | — | |
| EBITDA | 1,261 | 1,265 | 2,569 | 1,944 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 21.22 | 18.11 | 7.72 | 6.96 | — | — | — | — | — | |
| Price To Sales Ratio | 1.10 | 1.03 | 1.06 | 0.72 | — | — | — | — | — | |
| Gross Margin | 35.70 | 38.22 | 37.09 | 32.76 | — | — | — | — | — | |
| Operating Margin | 6.84 | 7.15 | 17.60 | 13.32 | — | — | — | — | — | |
| Net Margin | 5.31 | 5.66 | 13.91 | 10.43 | — | — | — | — | — | |
| Shares Outstanding | 160 | 173 | 186 | 197 | — | — | — | — | — | |
| Market Capitalization | 14,565 | 13,408 | 13,584 | 8,908 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Keaney Timothy F | Director | Sep 10 '26 | Sale | 94.02 | 4,300 | 404,286 | 36,502 | Sep 11 |
| Rice Walter Lynn JR | SVP, Chief Accounting Officer | Sep 10 '26 | Sale | 94.31 | 2,188 | 206,361 | 8,154 | Sep 11 |
| IGLESIAS LISA G | EVP, General Counsel | Sep 09 '26 | Sale | 94.44 | 4,000 | 377,747 | 25,453 | Sep 11 |
| Ahmed Elizabeth Claire | EVP, People & Communications | Apr 30 '26 | Sale | 80.14 | 12,000 | 961,680 | 42,587 | May 01 |
| Pyne Christopher W | EVP, Group Benefits | Mar 16 '26 | Sale | 72.47 | 4,852 | 351,624 | 52,268 | Mar 18 |
| IGLESIAS LISA G | EVP, General Counsel | Mar 09 '26 | Sale | 73.00 | 3,500 | 255,500 | 29,453 | Mar 11 |
| Keaney Timothy F | Director | Feb 18 '26 | Sale | 72.58 | 4,500 | 326,610 | 38,592 | Feb 20 |
| Egan Cynthia | Director | Feb 18 '26 | Sale | 73.00 | 9,000 | 657,032 | 42,846 | Feb 20 |
| Rice Walter Lynn JR | SVP, Chief Accounting Officer | Dec 09 '25 | Sale | 73.50 | 900 | 66,152 | 8,940 | Dec 11 |
| Zabel Steven Andrew | EVP, Chief Financial Officer | Nov 19 '25 | Sale | 76.38 | 7,500 | 572,865 | 113,807 | Nov 21 |
| Pyne Christopher W | EVP, Group Benefits | Nov 07 '25 | Sale | 78.04 | 4,000 | 312,148 | 51,372 | Nov 10 |
| Ahmed Elizabeth Claire | EVP, People & Communications | May 07 '25 | Sale | 80.00 | 10,000 | 800,000 | 51,170 | May 12 |
| DeVore Susan D. | Director | Mar 03 '25 | Sale | 80.88 | 10,000 | 808,788 | 27,396 | Mar 04 |
| IGLESIAS LISA G | EVP, General Counsel | Mar 03 '25 | Sale | 82.75 | 7,000 | 579,250 | 31,284 | Mar 04 |
| McKenney Richard P | President and CEO | Mar 03 '25 | Sale | 81.99 | 50,000 | 4,099,455 | 980,637 | Mar 04 |